Koshinski Asset Management Inc. Sells 19,931 Shares of Johnson & Johnson (NYSE:JNJ)

Koshinski Asset Management Inc. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 41.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,017 shares of the company's stock after selling 19,931 shares during the period. Koshinski Asset Management Inc.'s holdings in Johnson & Johnson were worth $4,392,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. ORG Partners LLC raised its holdings in shares of Johnson & Johnson by 63.6% in the fourth quarter. ORG Partners LLC now owns 11,416 shares of the company's stock valued at $1,791,000 after purchasing an additional 4,437 shares during the last quarter. NewEdge Wealth LLC increased its holdings in Johnson & Johnson by 14.8% during the fourth quarter. NewEdge Wealth LLC now owns 106,055 shares of the company's stock worth $16,623,000 after buying an additional 13,657 shares during the last quarter. Vaughan David Investments LLC IL increased its holdings in Johnson & Johnson by 1.0% during the fourth quarter. Vaughan David Investments LLC IL now owns 302,175 shares of the company's stock worth $47,363,000 after buying an additional 3,042 shares during the last quarter. Ellis Investment Partners LLC increased its holdings in Johnson & Johnson by 12.2% during the fourth quarter. Ellis Investment Partners LLC now owns 11,015 shares of the company's stock worth $1,726,000 after buying an additional 1,195 shares during the last quarter. Finally, Clarius Group LLC increased its holdings in Johnson & Johnson by 11.9% during the fourth quarter. Clarius Group LLC now owns 27,025 shares of the company's stock worth $4,236,000 after buying an additional 2,870 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on JNJ shares. Raymond James raised their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an "outperform" rating in a report on Wednesday, January 3rd. Morgan Stanley decreased their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set an "equal weight" rating for the company in a report on Wednesday. HSBC upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating and raised their price objective for the stock from $169.00 to $170.00 in a report on Thursday. Royal Bank of Canada cut their target price on shares of Johnson & Johnson from $181.00 to $175.00 and set an "outperform" rating for the company in a research report on Wednesday. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Monday. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $175.86.

Johnson & Johnson Price Performance

NYSE:JNJ traded up $2.19 during mid-day trading on Friday, hitting $147.93. 9,747,684 shares of the stock traded hands, compared to its average volume of 7,287,224. The business's 50-day moving average price is $156.15 and its 200 day moving average price is $155.63. The company has a market cap of $356.48 billion, a PE ratio of 9.22, a price-to-earnings-growth ratio of 2.39 and a beta of 0.53. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion during the quarter, compared to analysts' expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. Johnson & Johnson's revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.68 earnings per share. On average, analysts expect that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.35%. The ex-dividend date of this dividend is Monday, May 20th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.19. Johnson & Johnson's payout ratio is currently 30.92%.

Insiders Place Their Bets

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the business's stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares of the company's stock, valued at approximately $105,810,030.75. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, EVP Jennifer L. Taubert sold 59,397 shares of the business's stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of the business's stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company's stock, valued at $105,810,030.75. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.